 Richard Schulick
Concepts (913)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 180 | 2025 | 938 | 16.720 |
Why?
| | Pancreaticoduodenectomy | 65 | 2025 | 164 | 7.650 |
Why?
| | Adenocarcinoma | 77 | 2025 | 940 | 6.370 |
Why?
| | Carcinoma, Pancreatic Ductal | 51 | 2024 | 289 | 5.730 |
Why?
| | Pancreatectomy | 57 | 2025 | 253 | 5.360 |
Why?
| | Liver Neoplasms | 56 | 2024 | 786 | 3.620 |
Why?
| | Bile Duct Neoplasms | 14 | 2024 | 124 | 2.320 |
Why?
| | Hepatectomy | 38 | 2024 | 251 | 2.190 |
Why?
| | Neoadjuvant Therapy | 28 | 2025 | 404 | 2.180 |
Why?
| | Neuroendocrine Tumors | 13 | 2025 | 116 | 2.160 |
Why?
| | Cholangiocarcinoma | 12 | 2024 | 104 | 2.050 |
Why?
| | Common Bile Duct Neoplasms | 10 | 2025 | 30 | 1.860 |
Why?
| | Laparoscopy | 15 | 2024 | 466 | 1.840 |
Why?
| | Pancreatic Cyst | 12 | 2022 | 60 | 1.830 |
Why?
| | Survival Rate | 61 | 2025 | 1972 | 1.610 |
Why?
| | General Surgery | 7 | 2021 | 173 | 1.590 |
Why?
| | Neoplasm Recurrence, Local | 28 | 2024 | 1079 | 1.550 |
Why?
| | Stomach Neoplasms | 7 | 2024 | 122 | 1.520 |
Why?
| | Colorectal Neoplasms | 21 | 2014 | 806 | 1.500 |
Why?
| | Humans | 348 | 2025 | 137585 | 1.440 |
Why?
| | Pancreas | 16 | 2023 | 329 | 1.400 |
Why?
| | Carcinoma, Neuroendocrine | 8 | 2023 | 42 | 1.400 |
Why?
| | Prognosis | 69 | 2024 | 4030 | 1.380 |
Why?
| | Neoplasm Staging | 42 | 2024 | 1389 | 1.370 |
Why?
| | Cancer Vaccines | 8 | 2024 | 172 | 1.370 |
Why?
| | Aged | 173 | 2025 | 23961 | 1.310 |
Why?
| | Retrospective Studies | 112 | 2025 | 15657 | 1.300 |
Why?
| | Middle Aged | 187 | 2025 | 33479 | 1.290 |
Why?
| | Bile Ducts, Intrahepatic | 11 | 2012 | 78 | 1.260 |
Why?
| | Postoperative Complications | 29 | 2025 | 2654 | 1.200 |
Why?
| | Ampulla of Vater | 11 | 2025 | 42 | 1.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 22 | 2025 | 1692 | 1.180 |
Why?
| | Adenocarcinoma, Mucinous | 9 | 2023 | 80 | 1.150 |
Why?
| | Mesenteric Veins | 6 | 2025 | 24 | 1.100 |
Why?
| | Portal Vein | 8 | 2025 | 120 | 1.100 |
Why?
| | Female | 227 | 2025 | 73304 | 1.060 |
Why?
| | Male | 212 | 2025 | 67762 | 1.060 |
Why?
| | Chemotherapy, Adjuvant | 24 | 2025 | 389 | 1.020 |
Why?
| | Pancreatic Fistula | 6 | 2022 | 30 | 0.940 |
Why?
| | Carcinoma, Hepatocellular | 11 | 2016 | 362 | 0.940 |
Why?
| | Aged, 80 and over | 79 | 2025 | 7635 | 0.930 |
Why?
| | Pancreatic Ducts | 7 | 2012 | 85 | 0.920 |
Why?
| | Biomarkers, Tumor | 20 | 2024 | 1276 | 0.890 |
Why?
| | Robotics | 3 | 2015 | 94 | 0.890 |
Why?
| | Neoplasms, Second Primary | 4 | 2019 | 118 | 0.840 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2022 | 179 | 0.830 |
Why?
| | Colonic Neoplasms | 9 | 2024 | 258 | 0.780 |
Why?
| | Patient Care Team | 7 | 2021 | 631 | 0.780 |
Why?
| | Quality-Adjusted Life Years | 2 | 2013 | 113 | 0.770 |
Why?
| | Early Detection of Cancer | 6 | 2020 | 447 | 0.770 |
Why?
| | Combined Modality Therapy | 19 | 2024 | 1236 | 0.730 |
Why?
| | Follow-Up Studies | 37 | 2024 | 5131 | 0.730 |
Why?
| | Carcinoma | 5 | 2018 | 240 | 0.710 |
Why?
| | Internship and Residency | 4 | 2021 | 1147 | 0.690 |
Why?
| | Adult | 117 | 2025 | 37929 | 0.680 |
Why?
| | Treatment Outcome | 63 | 2025 | 10811 | 0.670 |
Why?
| | Listeria monocytogenes | 5 | 2012 | 126 | 0.660 |
Why?
| | Faculty, Medical | 2 | 2018 | 283 | 0.660 |
Why?
| | Learning Curve | 2 | 2024 | 72 | 0.660 |
Why?
| | Survival Analysis | 28 | 2024 | 1325 | 0.650 |
Why?
| | Lymphatic Metastasis | 24 | 2024 | 352 | 0.650 |
Why?
| | Cyclophosphamide | 6 | 2024 | 247 | 0.650 |
Why?
| | Tomography, X-Ray Computed | 24 | 2021 | 2691 | 0.650 |
Why?
| | Cost-Benefit Analysis | 2 | 2013 | 591 | 0.640 |
Why?
| | Tumor Microenvironment | 11 | 2025 | 674 | 0.640 |
Why?
| | Healthcare Disparities | 5 | 2014 | 654 | 0.630 |
Why?
| | Thrombelastography | 4 | 2024 | 154 | 0.630 |
Why?
| | Fluorouracil | 15 | 2025 | 208 | 0.620 |
Why?
| | Stents | 5 | 2011 | 527 | 0.620 |
Why?
| | Adenoma | 6 | 2025 | 230 | 0.620 |
Why?
| | Neoplasms | 12 | 2025 | 2671 | 0.610 |
Why?
| | Pancreatic Diseases | 7 | 2019 | 72 | 0.600 |
Why?
| | Immunotherapy | 13 | 2024 | 641 | 0.590 |
Why?
| | Proportional Hazards Models | 20 | 2023 | 1266 | 0.590 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 23 | 0.590 |
Why?
| | Vascular Surgical Procedures | 6 | 2025 | 303 | 0.580 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 44 | 0.550 |
Why?
| | Mentors | 3 | 2021 | 202 | 0.550 |
Why?
| | Databases, Factual | 9 | 2024 | 1357 | 0.540 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2008 | 38 | 0.540 |
Why?
| | Practice Patterns, Physicians' | 9 | 2025 | 1313 | 0.530 |
Why?
| | Lymph Node Excision | 4 | 2024 | 171 | 0.520 |
Why?
| | Hospitals | 3 | 2019 | 691 | 0.520 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2024 | 220 | 0.510 |
Why?
| | Leadership | 2 | 2018 | 388 | 0.510 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 114 | 0.510 |
Why?
| | Adrenalectomy | 2 | 2006 | 68 | 0.500 |
Why?
| | Gallbladder Neoplasms | 5 | 2024 | 23 | 0.500 |
Why?
| | Lung Neoplasms | 8 | 2023 | 2526 | 0.490 |
Why?
| | Cholecystectomy | 4 | 2014 | 62 | 0.490 |
Why?
| | Antineoplastic Agents | 11 | 2021 | 2129 | 0.490 |
Why?
| | Education, Medical, Continuing | 2 | 2015 | 127 | 0.490 |
Why?
| | Carcinoma, Papillary | 6 | 2017 | 81 | 0.480 |
Why?
| | Quality Assurance, Health Care | 2 | 2015 | 322 | 0.470 |
Why?
| | Benchmarking | 3 | 2021 | 186 | 0.460 |
Why?
| | Neoplasm Invasiveness | 21 | 2025 | 510 | 0.460 |
Why?
| | Cholelithiasis | 1 | 2014 | 38 | 0.450 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 3 | 2016 | 213 | 0.450 |
Why?
| | Peritoneal Neoplasms | 3 | 2024 | 93 | 0.450 |
Why?
| | Bile Ducts, Extrahepatic | 3 | 2012 | 22 | 0.450 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 21 | 0.450 |
Why?
| | Membrane Glycoproteins | 4 | 2025 | 500 | 0.440 |
Why?
| | Lymphedema | 1 | 2014 | 24 | 0.440 |
Why?
| | Biomedical Research | 2 | 2013 | 692 | 0.440 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 306 | 0.440 |
Why?
| | Pheochromocytoma | 3 | 2013 | 59 | 0.430 |
Why?
| | Metastasectomy | 2 | 2024 | 20 | 0.430 |
Why?
| | Radiosurgery | 3 | 2024 | 344 | 0.420 |
Why?
| | SEER Program | 11 | 2011 | 227 | 0.420 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2014 | 115 | 0.420 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2013 | 89 | 0.420 |
Why?
| | Esophageal Neoplasms | 4 | 2023 | 321 | 0.420 |
Why?
| | Liver Neoplasms, Experimental | 4 | 2014 | 31 | 0.420 |
Why?
| | Cytoreduction Surgical Procedures | 3 | 2024 | 63 | 0.420 |
Why?
| | Genetic Predisposition to Disease | 7 | 2018 | 2426 | 0.410 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 385 | 0.410 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 122 | 0.410 |
Why?
| | Catheter Ablation | 11 | 2012 | 350 | 0.410 |
Why?
| | Risk Assessment | 19 | 2020 | 3457 | 0.400 |
Why?
| | Nomograms | 3 | 2022 | 54 | 0.400 |
Why?
| | Leucovorin | 6 | 2025 | 81 | 0.400 |
Why?
| | Deoxycytidine | 7 | 2025 | 179 | 0.390 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2009 | 18 | 0.380 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 75 | 0.380 |
Why?
| | Rectal Neoplasms | 5 | 2017 | 149 | 0.380 |
Why?
| | Incidental Findings | 7 | 2021 | 87 | 0.380 |
Why?
| | Kaplan-Meier Estimate | 19 | 2018 | 889 | 0.370 |
Why?
| | Cystadenoma, Serous | 4 | 2020 | 21 | 0.370 |
Why?
| | Immunohistochemistry | 20 | 2019 | 1738 | 0.370 |
Why?
| | Diagnosis, Differential | 9 | 2022 | 1483 | 0.370 |
Why?
| | Research Personnel | 1 | 2013 | 173 | 0.370 |
Why?
| | Carcinoma, Islet Cell | 3 | 2006 | 4 | 0.370 |
Why?
| | Cohort Studies | 21 | 2024 | 5742 | 0.370 |
Why?
| | Sigmoid Neoplasms | 1 | 2011 | 5 | 0.360 |
Why?
| | Vascular Neoplasms | 4 | 2020 | 18 | 0.360 |
Why?
| | Interleukin-2 | 4 | 2007 | 455 | 0.360 |
Why?
| | Solitary Fibrous Tumors | 1 | 2011 | 5 | 0.360 |
Why?
| | Predictive Value of Tests | 17 | 2024 | 2031 | 0.350 |
Why?
| | Palliative Care | 6 | 2012 | 758 | 0.350 |
Why?
| | Mice, Inbred BALB C | 12 | 2021 | 1272 | 0.350 |
Why?
| | United States | 35 | 2024 | 14841 | 0.350 |
Why?
| | Hepatic Artery | 5 | 2020 | 62 | 0.340 |
Why?
| | Gamma Rays | 2 | 2021 | 57 | 0.340 |
Why?
| | Patient Care Planning | 4 | 2018 | 157 | 0.340 |
Why?
| | Lymph Nodes | 8 | 2024 | 491 | 0.340 |
Why?
| | Breast Neoplasms | 3 | 2024 | 2253 | 0.330 |
Why?
| | Cyst Fluid | 4 | 2022 | 25 | 0.330 |
Why?
| | Positron-Emission Tomography | 7 | 2008 | 294 | 0.330 |
Why?
| | MAP Kinase Kinase 4 | 2 | 2006 | 29 | 0.330 |
Why?
| | Integrin alpha2 | 1 | 2009 | 3 | 0.320 |
Why?
| | Disease-Free Survival | 13 | 2023 | 686 | 0.320 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2023 | 77 | 0.310 |
Why?
| | Cystadenocarcinoma, Mucinous | 3 | 2015 | 13 | 0.310 |
Why?
| | Mice | 29 | 2025 | 17787 | 0.310 |
Why?
| | Referral and Consultation | 4 | 2024 | 786 | 0.310 |
Why?
| | Abdominal Abscess | 2 | 2011 | 27 | 0.310 |
Why?
| | Octreotide | 1 | 2009 | 26 | 0.310 |
Why?
| | Mutation | 11 | 2016 | 3958 | 0.310 |
Why?
| | Length of Stay | 10 | 2021 | 1215 | 0.300 |
Why?
| | Adenoma, Islet Cell | 2 | 2006 | 8 | 0.300 |
Why?
| | Risk Factors | 31 | 2024 | 10388 | 0.300 |
Why?
| | Liver Transplantation | 6 | 2024 | 871 | 0.300 |
Why?
| | CA-19-9 Antigen | 4 | 2024 | 22 | 0.300 |
Why?
| | Klatskin Tumor | 3 | 2021 | 15 | 0.300 |
Why?
| | Radiotherapy, Adjuvant | 11 | 2024 | 220 | 0.300 |
Why?
| | Time Factors | 20 | 2021 | 6828 | 0.300 |
Why?
| | Internationality | 2 | 2020 | 155 | 0.290 |
Why?
| | Chemoradiotherapy | 6 | 2022 | 225 | 0.290 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 1999 | 63 | 0.290 |
Why?
| | Robotic Surgical Procedures | 2 | 2021 | 130 | 0.290 |
Why?
| | Choledochal Cyst | 1 | 2008 | 19 | 0.290 |
Why?
| | Duodenostomy | 1 | 2007 | 5 | 0.280 |
Why?
| | Jejunostomy | 1 | 2007 | 13 | 0.280 |
Why?
| | Pain, Postoperative | 2 | 2021 | 265 | 0.270 |
Why?
| | Digestive System Surgical Procedures | 3 | 2019 | 106 | 0.270 |
Why?
| | Operative Time | 3 | 2024 | 145 | 0.270 |
Why?
| | Biliary Tract Surgical Procedures | 3 | 2021 | 26 | 0.270 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2016 | 25 | 0.270 |
Why?
| | Biomarkers | 5 | 2022 | 4149 | 0.270 |
Why?
| | Gastrectomy | 2 | 2024 | 126 | 0.270 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2024 | 152 | 0.260 |
Why?
| | Cushing Syndrome | 1 | 2006 | 10 | 0.260 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2017 | 43 | 0.260 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2025 | 210 | 0.260 |
Why?
| | Hyperamylasemia | 2 | 2022 | 4 | 0.260 |
Why?
| | von Hippel-Lindau Disease | 1 | 2006 | 12 | 0.260 |
Why?
| | Animals | 39 | 2025 | 36940 | 0.260 |
Why?
| | Anastomosis, Surgical | 4 | 2015 | 153 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.250 |
Why?
| | Interdisciplinary Communication | 3 | 2021 | 191 | 0.250 |
Why?
| | Prospective Studies | 23 | 2024 | 7604 | 0.250 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2006 | 143 | 0.250 |
Why?
| | Esophagectomy | 2 | 2022 | 131 | 0.250 |
Why?
| | DNA Helicases | 3 | 2012 | 145 | 0.250 |
Why?
| | Liver | 6 | 2020 | 1943 | 0.240 |
Why?
| | Carcinoma in Situ | 3 | 2012 | 49 | 0.240 |
Why?
| | Endosonography | 4 | 2018 | 156 | 0.240 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2018 | 142 | 0.240 |
Why?
| | Pancreatitis | 3 | 2022 | 134 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 3 | 2013 | 916 | 0.240 |
Why?
| | Cell Proliferation | 8 | 2021 | 2475 | 0.240 |
Why?
| | Precancerous Conditions | 4 | 2011 | 169 | 0.240 |
Why?
| | Arteries | 2 | 2019 | 269 | 0.240 |
Why?
| | Chemoembolization, Therapeutic | 4 | 2012 | 91 | 0.240 |
Why?
| | Cell Line, Tumor | 13 | 2025 | 3412 | 0.230 |
Why?
| | Hospital Mortality | 10 | 2020 | 911 | 0.230 |
Why?
| | Genetic Engineering | 1 | 2006 | 93 | 0.230 |
Why?
| | Publishing | 1 | 2007 | 147 | 0.230 |
Why?
| | Membrane Proteins | 4 | 2021 | 1164 | 0.230 |
Why?
| | Lectins, C-Type | 2 | 2024 | 67 | 0.230 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 217 | 0.230 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2016 | 12 | 0.230 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 1994 | 137 | 0.220 |
Why?
| | Smad4 Protein | 4 | 2013 | 38 | 0.220 |
Why?
| | Immunotherapy, Adoptive | 2 | 2025 | 327 | 0.220 |
Why?
| | Biliary Tract Neoplasms | 4 | 2006 | 30 | 0.220 |
Why?
| | Tumor Cells, Cultured | 6 | 2021 | 955 | 0.220 |
Why?
| | Baltimore | 5 | 2018 | 60 | 0.220 |
Why?
| | T-Lymphocytes | 4 | 2024 | 1996 | 0.220 |
Why?
| | Perioperative Care | 2 | 2024 | 178 | 0.220 |
Why?
| | Hepatoblastoma | 1 | 2024 | 46 | 0.220 |
Why?
| | Cystadenoma, Mucinous | 2 | 2015 | 13 | 0.210 |
Why?
| | Quality Improvement | 3 | 2023 | 1178 | 0.210 |
Why?
| | Immunity | 2 | 2021 | 143 | 0.210 |
Why?
| | Quality of Life | 6 | 2020 | 2892 | 0.210 |
Why?
| | Reoperation | 6 | 2016 | 573 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2025 | 872 | 0.200 |
Why?
| | Chi-Square Distribution | 8 | 2015 | 530 | 0.200 |
Why?
| | Somatostatinoma | 1 | 2002 | 1 | 0.200 |
Why?
| | Nuclear Proteins | 4 | 2012 | 712 | 0.200 |
Why?
| | Genes, Tumor Suppressor | 5 | 2011 | 86 | 0.200 |
Why?
| | Proto-Oncogene Proteins | 6 | 2012 | 648 | 0.200 |
Why?
| | Splenectomy | 3 | 2020 | 62 | 0.200 |
Why?
| | Ephrin-B2 | 2 | 2021 | 47 | 0.200 |
Why?
| | Immunologic Factors | 2 | 2018 | 236 | 0.190 |
Why?
| | Benzamides | 3 | 2008 | 216 | 0.190 |
Why?
| | Patient Safety | 3 | 2021 | 314 | 0.190 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 206 | 0.190 |
Why?
| | Multivariate Analysis | 9 | 2016 | 1509 | 0.190 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 2 | 2012 | 11 | 0.190 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 13 | 0.190 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 411 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 27 | 0.190 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.180 |
Why?
| | Carcinoembryonic Antigen | 5 | 2015 | 39 | 0.180 |
Why?
| | Incidence | 7 | 2019 | 2804 | 0.180 |
Why?
| | Quinazolines | 3 | 2013 | 251 | 0.180 |
Why?
| | Lymphocytes | 2 | 2020 | 397 | 0.180 |
Why?
| | Paternalism | 1 | 2021 | 4 | 0.180 |
Why?
| | Fibrosis | 3 | 2021 | 552 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3566 | 0.180 |
Why?
| | Hospitals, Teaching | 3 | 2018 | 118 | 0.180 |
Why?
| | Albumins | 3 | 2025 | 114 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.170 |
Why?
| | Recombinant Proteins | 2 | 2006 | 1353 | 0.170 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2020 | 73 | 0.170 |
Why?
| | Gastroenterology | 1 | 2023 | 180 | 0.170 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 58 | 0.170 |
Why?
| | Oxycodone | 1 | 2021 | 42 | 0.170 |
Why?
| | Employment | 1 | 2022 | 178 | 0.170 |
Why?
| | Sarcoma | 2 | 2016 | 188 | 0.170 |
Why?
| | Access to Information | 1 | 2021 | 49 | 0.170 |
Why?
| | Disease Progression | 8 | 2022 | 2757 | 0.170 |
Why?
| | Melanoma | 2 | 2022 | 760 | 0.170 |
Why?
| | Surgeons | 1 | 2025 | 297 | 0.170 |
Why?
| | Communication | 2 | 2021 | 879 | 0.170 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.170 |
Why?
| | Tattooing | 2 | 2010 | 14 | 0.170 |
Why?
| | Serotonin | 3 | 2012 | 323 | 0.170 |
Why?
| | Checklist | 1 | 2021 | 93 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 80 | 0.170 |
Why?
| | Tumor Burden | 6 | 2022 | 309 | 0.170 |
Why?
| | Sarcopenia | 2 | 2012 | 83 | 0.170 |
Why?
| | Body Composition | 1 | 2024 | 684 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 173 | 0.170 |
Why?
| | Pancreaticojejunostomy | 1 | 2020 | 8 | 0.170 |
Why?
| | Comprehension | 1 | 2022 | 172 | 0.170 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 112 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 801 | 0.160 |
Why?
| | Feasibility Studies | 5 | 2020 | 956 | 0.160 |
Why?
| | Health Literacy | 1 | 2022 | 168 | 0.160 |
Why?
| | Faculty | 1 | 2021 | 147 | 0.160 |
Why?
| | Operating Rooms | 1 | 2021 | 123 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2017 | 449 | 0.160 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 66 | 0.160 |
Why?
| | Algorithms | 2 | 2019 | 1704 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2021 | 145 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2023 | 250 | 0.160 |
Why?
| | Statistics, Nonparametric | 6 | 2011 | 431 | 0.160 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2012 | 430 | 0.160 |
Why?
| | Preoperative Care | 9 | 2018 | 362 | 0.160 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 77 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 179 | 0.160 |
Why?
| | Patient-Centered Care | 2 | 2022 | 530 | 0.150 |
Why?
| | Kidney Transplantation | 3 | 1997 | 708 | 0.150 |
Why?
| | Japan | 3 | 2025 | 115 | 0.150 |
Why?
| | Age Factors | 9 | 2022 | 3295 | 0.150 |
Why?
| | Genetic Testing | 3 | 2018 | 460 | 0.150 |
Why?
| | Mice, Inbred C57BL | 8 | 2021 | 5757 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2021 | 245 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 34 | 0.150 |
Why?
| | Radiology | 1 | 2021 | 180 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 209 | 0.150 |
Why?
| | Career Choice | 2 | 2018 | 219 | 0.150 |
Why?
| | Adolescent | 21 | 2022 | 21513 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 1999 | 65 | 0.150 |
Why?
| | Safety Management | 2 | 2010 | 124 | 0.150 |
Why?
| | Neoplasm Proteins | 3 | 2008 | 434 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 188 | 0.150 |
Why?
| | Analysis of Variance | 8 | 2013 | 1316 | 0.150 |
Why?
| | ras Proteins | 4 | 2012 | 153 | 0.150 |
Why?
| | Health Resources | 1 | 2019 | 120 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 190 | 0.150 |
Why?
| | Thalidomide | 1 | 2018 | 40 | 0.150 |
Why?
| | Flow Cytometry | 5 | 2019 | 1178 | 0.140 |
Why?
| | Europe | 4 | 2021 | 414 | 0.140 |
Why?
| | Sentinel Surveillance | 1 | 2018 | 49 | 0.140 |
Why?
| | Thrombophilia | 1 | 2018 | 83 | 0.140 |
Why?
| | Immunomodulation | 1 | 2018 | 98 | 0.140 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 77 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 806 | 0.140 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2019 | 125 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 3 | 2018 | 417 | 0.140 |
Why?
| | Signal Transduction | 9 | 2024 | 5079 | 0.140 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 79 | 0.140 |
Why?
| | Job Satisfaction | 2 | 2018 | 218 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1994 | 1091 | 0.140 |
Why?
| | Patient Compliance | 1 | 2021 | 581 | 0.130 |
Why?
| | Neutrophils | 3 | 2019 | 1238 | 0.130 |
Why?
| | DNA Mutational Analysis | 4 | 2016 | 399 | 0.130 |
Why?
| | Trastuzumab | 1 | 2017 | 96 | 0.130 |
Why?
| | Maryland | 4 | 2013 | 60 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2015 | 249 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 44 | 0.130 |
Why?
| | Societies, Medical | 2 | 2018 | 820 | 0.130 |
Why?
| | DNA Mismatch Repair | 1 | 2016 | 49 | 0.130 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 348 | 0.130 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 38 | 0.130 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 34 | 0.130 |
Why?
| | Ki-67 Antigen | 2 | 2013 | 112 | 0.130 |
Why?
| | Telomere | 2 | 2012 | 280 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2020 | 347 | 0.130 |
Why?
| | Patient Selection | 4 | 2024 | 696 | 0.130 |
Why?
| | Radiotherapy | 2 | 2019 | 201 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2018 | 224 | 0.130 |
Why?
| | Neoplasm Metastasis | 5 | 2012 | 658 | 0.120 |
Why?
| | Receptors, Immunologic | 1 | 2017 | 216 | 0.120 |
Why?
| | Viscera | 1 | 2015 | 17 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.120 |
Why?
| | Efficiency | 1 | 2016 | 99 | 0.120 |
Why?
| | Hepatitis | 2 | 2006 | 48 | 0.120 |
Why?
| | Neoplasm Grading | 5 | 2016 | 307 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2008 | 434 | 0.120 |
Why?
| | Young Adult | 16 | 2022 | 13209 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2025 | 5778 | 0.120 |
Why?
| | Constriction, Pathologic | 4 | 2011 | 245 | 0.120 |
Why?
| | Induction Chemotherapy | 1 | 2016 | 76 | 0.120 |
Why?
| | Antigens, Neoplasm | 2 | 2024 | 319 | 0.120 |
Why?
| | Cholestasis | 3 | 2011 | 235 | 0.120 |
Why?
| | Cannabis | 1 | 2023 | 494 | 0.120 |
Why?
| | Logistic Models | 5 | 2016 | 2074 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Piperazines | 2 | 2008 | 350 | 0.120 |
Why?
| | Decision Making | 2 | 2012 | 900 | 0.120 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2010 | 94 | 0.120 |
Why?
| | MicroRNAs | 2 | 2012 | 692 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 385 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1396 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1081 | 0.110 |
Why?
| | Caregivers | 1 | 2022 | 877 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 580 | 0.110 |
Why?
| | Practice Guidelines as Topic | 3 | 2024 | 1587 | 0.110 |
Why?
| | Capecitabine | 4 | 2017 | 45 | 0.110 |
Why?
| | Perioperative Period | 2 | 2011 | 56 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 44 | 0.110 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1000 | 0.110 |
Why?
| | Spleen | 1 | 2016 | 514 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 50 | 0.110 |
Why?
| | Genome | 2 | 2016 | 300 | 0.110 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 267 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2014 | 171 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 855 | 0.110 |
Why?
| | Pyrimidines | 2 | 2008 | 470 | 0.110 |
Why?
| | Propensity Score | 3 | 2025 | 294 | 0.110 |
Why?
| | Mitotic Index | 1 | 2013 | 25 | 0.110 |
Why?
| | Metabolomics | 1 | 2019 | 678 | 0.110 |
Why?
| | Colectomy | 2 | 2012 | 100 | 0.110 |
Why?
| | Pancreas, Exocrine | 1 | 2013 | 7 | 0.110 |
Why?
| | Cystadenoma | 1 | 2013 | 6 | 0.110 |
Why?
| | Acinar Cells | 1 | 2013 | 13 | 0.110 |
Why?
| | Paclitaxel | 2 | 2025 | 230 | 0.110 |
Why?
| | Exome | 2 | 2011 | 231 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2016 | 451 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 139 | 0.100 |
Why?
| | Isoantigens | 1 | 1993 | 15 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2021 | 1069 | 0.100 |
Why?
| | Enzyme Precursors | 1 | 2013 | 15 | 0.100 |
Why?
| | Graft Rejection | 2 | 1994 | 624 | 0.100 |
Why?
| | Cell Movement | 3 | 2022 | 967 | 0.100 |
Why?
| | Survivors | 2 | 2015 | 493 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2016 | 397 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2015 | 190 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 1997 | 890 | 0.100 |
Why?
| | Cholangiography | 3 | 2007 | 17 | 0.100 |
Why?
| | Protein C | 1 | 2013 | 59 | 0.100 |
Why?
| | Radiopharmaceuticals | 3 | 2008 | 178 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2008 | 135 | 0.100 |
Why?
| | Psoas Muscles | 1 | 2012 | 13 | 0.100 |
Why?
| | Tissue Array Analysis | 5 | 2011 | 57 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 2 | 2011 | 327 | 0.100 |
Why?
| | Biliopancreatic Diversion | 1 | 2012 | 1 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2011 | 789 | 0.100 |
Why?
| | Safety | 1 | 2014 | 338 | 0.100 |
Why?
| | Mice, Nude | 5 | 2020 | 698 | 0.100 |
Why?
| | Hemangioma | 1 | 2012 | 48 | 0.090 |
Why?
| | Carcinoma, Large Cell | 1 | 2012 | 16 | 0.090 |
Why?
| | Metoclopramide | 1 | 2012 | 19 | 0.090 |
Why?
| | Radiography | 5 | 2016 | 822 | 0.090 |
Why?
| | DNA Methylation | 4 | 2008 | 643 | 0.090 |
Why?
| | Ataxia Telangiectasia | 1 | 2011 | 20 | 0.090 |
Why?
| | Papilloma, Intraductal | 1 | 2011 | 3 | 0.090 |
Why?
| | Biological Therapy | 1 | 2012 | 29 | 0.090 |
Why?
| | Biopsy, Needle | 3 | 2011 | 189 | 0.090 |
Why?
| | Loss of Heterozygosity | 1 | 2012 | 51 | 0.090 |
Why?
| | Silk | 1 | 2011 | 2 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2006 | 1242 | 0.090 |
Why?
| | Glycolipids | 1 | 2012 | 42 | 0.090 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2011 | 7 | 0.090 |
Why?
| | Odds Ratio | 5 | 2016 | 1070 | 0.090 |
Why?
| | X Chromosome Inactivation | 2 | 2013 | 25 | 0.090 |
Why?
| | Hyalin | 1 | 2011 | 6 | 0.090 |
Why?
| | Hepatic Duct, Common | 1 | 2011 | 6 | 0.090 |
Why?
| | Injections, Intra-Arterial | 1 | 2011 | 27 | 0.090 |
Why?
| | Shock, Cardiogenic | 1 | 2012 | 63 | 0.090 |
Why?
| | Comorbidity | 5 | 2022 | 1622 | 0.090 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4295 | 0.090 |
Why?
| | Carcinoid Tumor | 1 | 2011 | 26 | 0.090 |
Why?
| | Cysts | 1 | 2012 | 113 | 0.090 |
Why?
| | Liver Cirrhosis | 3 | 2008 | 316 | 0.090 |
Why?
| | Gentamicins | 1 | 2011 | 54 | 0.090 |
Why?
| | Carcinoma, Small Cell | 1 | 2012 | 172 | 0.090 |
Why?
| | Point Mutation | 1 | 2012 | 235 | 0.090 |
Why?
| | Sutures | 1 | 2011 | 58 | 0.090 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 515 | 0.090 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 213 | 0.090 |
Why?
| | Neoplasm Transplantation | 3 | 2020 | 257 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2013 | 255 | 0.090 |
Why?
| | Choice Behavior | 1 | 2012 | 170 | 0.090 |
Why?
| | Gene Expression | 3 | 2019 | 1502 | 0.090 |
Why?
| | Axons | 1 | 2012 | 198 | 0.090 |
Why?
| | Asia | 2 | 2021 | 71 | 0.090 |
Why?
| | Registries | 4 | 2012 | 2035 | 0.090 |
Why?
| | Drainage | 2 | 2008 | 173 | 0.080 |
Why?
| | Panniculitis, Peritoneal | 1 | 2010 | 1 | 0.080 |
Why?
| | Surgery Department, Hospital | 1 | 2010 | 20 | 0.080 |
Why?
| | Transcriptome | 1 | 2016 | 971 | 0.080 |
Why?
| | Antigens | 1 | 2012 | 357 | 0.080 |
Why?
| | Ovarian Neoplasms | 2 | 2007 | 565 | 0.080 |
Why?
| | Liver Function Tests | 2 | 2007 | 114 | 0.080 |
Why?
| | Mesentery | 1 | 2010 | 48 | 0.080 |
Why?
| | Genital Neoplasms, Female | 1 | 2011 | 90 | 0.080 |
Why?
| | Internal-External Control | 1 | 2010 | 71 | 0.080 |
Why?
| | Embolization, Therapeutic | 1 | 2012 | 229 | 0.080 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2009 | 10 | 0.080 |
Why?
| | Pandemics | 3 | 2023 | 1639 | 0.080 |
Why?
| | Morbidity | 4 | 2012 | 324 | 0.080 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2009 | 32 | 0.080 |
Why?
| | Collagen Type IV | 1 | 2009 | 28 | 0.080 |
Why?
| | Cadherins | 1 | 2011 | 206 | 0.080 |
Why?
| | Uncertainty | 1 | 2010 | 128 | 0.080 |
Why?
| | Drug Synergism | 3 | 2007 | 382 | 0.080 |
Why?
| | Sex Factors | 4 | 2022 | 2071 | 0.080 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2006 | 12 | 0.080 |
Why?
| | Adenoma, Liver Cell | 1 | 2009 | 5 | 0.080 |
Why?
| | Hospitals, University | 2 | 2010 | 182 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2008 | 283 | 0.080 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 332 | 0.080 |
Why?
| | Biofilms | 1 | 2011 | 260 | 0.080 |
Why?
| | Chyle | 1 | 2008 | 4 | 0.070 |
Why?
| | ROC Curve | 2 | 2024 | 554 | 0.070 |
Why?
| | Chylous Ascites | 1 | 2008 | 6 | 0.070 |
Why?
| | Medical Records | 1 | 2009 | 177 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 354 | 0.070 |
Why?
| | Suture Techniques | 1 | 2009 | 122 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 176 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2016 | 2828 | 0.070 |
Why?
| | Hepatitis, Viral, Human | 1 | 2008 | 25 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2012 | 512 | 0.070 |
Why?
| | Annexins | 1 | 2008 | 3 | 0.070 |
Why?
| | Laparotomy | 1 | 2008 | 109 | 0.070 |
Why?
| | Antibodies | 2 | 2009 | 410 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2010 | 297 | 0.070 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2007 | 4 | 0.070 |
Why?
| | Erlotinib Hydrochloride | 3 | 2013 | 72 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 1477 | 0.070 |
Why?
| | Gastroscopy | 1 | 2007 | 19 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 617 | 0.070 |
Why?
| | Gastric Emptying | 1 | 2007 | 38 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 412 | 0.070 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1502 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 22 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 669 | 0.070 |
Why?
| | Histiocytosis, Sinus | 1 | 2007 | 8 | 0.070 |
Why?
| | Blood Urea Nitrogen | 1 | 2007 | 54 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 450 | 0.070 |
Why?
| | Transaminases | 1 | 2007 | 24 | 0.070 |
Why?
| | Electrocoagulation | 1 | 2007 | 40 | 0.070 |
Why?
| | Anus Neoplasms | 1 | 2007 | 33 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2013 | 1096 | 0.070 |
Why?
| | Hormones, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | Pyrroles | 1 | 2008 | 213 | 0.070 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 132 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 101 | 0.070 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2007 | 52 | 0.070 |
Why?
| | Receptors, Somatostatin | 1 | 2006 | 25 | 0.070 |
Why?
| | International Agencies | 3 | 2011 | 35 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 284 | 0.070 |
Why?
| | HIV-1 | 1 | 1993 | 864 | 0.070 |
Why?
| | Adrenal Cortex | 1 | 2006 | 29 | 0.060 |
Why?
| | Somatostatin | 1 | 2006 | 61 | 0.060 |
Why?
| | Thymidylate Synthase | 1 | 2006 | 12 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2022 | 3015 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1774 | 0.060 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 178 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 158 | 0.060 |
Why?
| | Patient Readmission | 1 | 2012 | 697 | 0.060 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1142 | 0.060 |
Why?
| | Exonucleases | 1 | 2006 | 9 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2009 | 483 | 0.060 |
Why?
| | Apoptosis | 4 | 2021 | 2553 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2013 | 1991 | 0.060 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2007 | 210 | 0.060 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 40 | 0.060 |
Why?
| | Paraganglioma | 1 | 2006 | 52 | 0.060 |
Why?
| | Organizational Culture | 2 | 2021 | 148 | 0.060 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 322 | 0.060 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2006 | 145 | 0.060 |
Why?
| | Pilot Projects | 3 | 2023 | 1710 | 0.060 |
Why?
| | B7-1 Antigen | 1 | 2005 | 58 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 56 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 900 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2008 | 614 | 0.060 |
Why?
| | Hospital Costs | 1 | 2005 | 117 | 0.060 |
Why?
| | Indoles | 1 | 2008 | 412 | 0.060 |
Why?
| | Sweden | 1 | 2025 | 101 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 217 | 0.060 |
Why?
| | Proteomics | 2 | 2008 | 1111 | 0.060 |
Why?
| | Pylorus | 1 | 2024 | 18 | 0.060 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 28 | 0.060 |
Why?
| | Postoperative Period | 2 | 2020 | 342 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 338 | 0.060 |
Why?
| | Galectin 3 | 1 | 2004 | 20 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 143 | 0.060 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1062 | 0.060 |
Why?
| | Neuropilin-1 | 1 | 2004 | 9 | 0.050 |
Why?
| | Probability | 1 | 2005 | 304 | 0.050 |
Why?
| | Periodicals as Topic | 1 | 2007 | 211 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2018 | 3556 | 0.050 |
Why?
| | Celiac Artery | 2 | 2020 | 17 | 0.050 |
Why?
| | Age Distribution | 1 | 2005 | 392 | 0.050 |
Why?
| | Camptothecin | 1 | 2004 | 116 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 375 | 0.050 |
Why?
| | Mesenteric Artery, Superior | 2 | 2020 | 17 | 0.050 |
Why?
| | Canada | 2 | 2018 | 418 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 4 | 1985 | 155 | 0.050 |
Why?
| | Protein Array Analysis | 1 | 2004 | 57 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 213 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 660 | 0.050 |
Why?
| | Proteome | 1 | 2008 | 472 | 0.050 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 41 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2025 | 229 | 0.050 |
Why?
| | Cholecystitis | 1 | 2003 | 24 | 0.050 |
Why?
| | Pyridines | 1 | 2007 | 506 | 0.050 |
Why?
| | Child | 6 | 2009 | 21935 | 0.050 |
Why?
| | Genomic Instability | 1 | 2003 | 53 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 315 | 0.050 |
Why?
| | Transcription Factors | 1 | 2011 | 1719 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2025 | 565 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2003 | 168 | 0.050 |
Why?
| | Reproducibility of Results | 4 | 2014 | 3284 | 0.050 |
Why?
| | Mass Screening | 2 | 2010 | 1287 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 403 | 0.050 |
Why?
| | Postoperative Hemorrhage | 1 | 2023 | 86 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 10 | 0.050 |
Why?
| | Biopsy | 3 | 2013 | 1129 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 280 | 0.050 |
Why?
| | Health Care Costs | 1 | 2005 | 398 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2024 | 301 | 0.050 |
Why?
| | Chromogranins | 2 | 2012 | 15 | 0.050 |
Why?
| | Pneumonectomy | 1 | 2023 | 152 | 0.050 |
Why?
| | MutL Protein Homolog 1 | 2 | 2016 | 12 | 0.050 |
Why?
| | X-linked Nuclear Protein | 2 | 2012 | 9 | 0.050 |
Why?
| | Radiotherapy, Conformal | 2 | 2012 | 70 | 0.050 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 557 | 0.050 |
Why?
| | Co-Repressor Proteins | 2 | 2012 | 18 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 683 | 0.050 |
Why?
| | Jaundice | 2 | 2011 | 14 | 0.050 |
Why?
| | Chemokines | 1 | 2022 | 228 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 606 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 310 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 76 | 0.050 |
Why?
| | Neuropeptides | 1 | 2021 | 73 | 0.040 |
Why?
| | Prevalence | 2 | 2023 | 2734 | 0.040 |
Why?
| | Clone Cells | 2 | 2012 | 265 | 0.040 |
Why?
| | Smoking | 1 | 2009 | 1627 | 0.040 |
Why?
| | Antigens, CD | 1 | 2024 | 521 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 217 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 32 | 0.040 |
Why?
| | Pedigree | 2 | 2012 | 514 | 0.040 |
Why?
| | Phenotype | 3 | 2015 | 3196 | 0.040 |
Why?
| | Chromatin Assembly and Disassembly | 2 | 2011 | 104 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 8 | 0.040 |
Why?
| | Portal System | 1 | 2020 | 14 | 0.040 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2000 | 11 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 147 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1946 | 0.040 |
Why?
| | Contrast Media | 3 | 2010 | 467 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 86 | 0.040 |
Why?
| | Terminology as Topic | 2 | 2013 | 216 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 635 | 0.040 |
Why?
| | Educational Status | 1 | 2022 | 470 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 73 | 0.040 |
Why?
| | Molecular Chaperones | 2 | 2012 | 195 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2025 | 2167 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2020 | 201 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 664 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 528 | 0.040 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2012 | 57 | 0.040 |
Why?
| | Mitochondria | 1 | 2006 | 948 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 329 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1007 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 364 | 0.040 |
Why?
| | Drug Utilization Review | 1 | 2019 | 57 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 116 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 730 | 0.040 |
Why?
| | Abdominal Pain | 2 | 2011 | 145 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 278 | 0.040 |
Why?
| | Antigens, Differentiation | 2 | 2011 | 83 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2844 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1988 | 22 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 317 | 0.040 |
Why?
| | Organizational Innovation | 2 | 2010 | 140 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 812 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1430 | 0.040 |
Why?
| | Ketoconazole | 1 | 1997 | 4 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 852 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.040 |
Why?
| | HIV Infections | 1 | 1993 | 2836 | 0.040 |
Why?
| | Immunocompetence | 1 | 1997 | 42 | 0.040 |
Why?
| | Inflammation | 2 | 2006 | 2837 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 2085 | 0.040 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 307 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 545 | 0.040 |
Why?
| | Up-Regulation | 3 | 2007 | 843 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2013 | 2833 | 0.030 |
Why?
| | Sclerosis | 2 | 2010 | 13 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2019 | 275 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2017 | 124 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 365 | 0.030 |
Why?
| | MutS Homolog 2 Protein | 1 | 2016 | 15 | 0.030 |
Why?
| | Clinical Audit | 1 | 2016 | 14 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 898 | 0.030 |
Why?
| | Ultrasonography | 2 | 2011 | 759 | 0.030 |
Why?
| | Patient Satisfaction | 2 | 2012 | 660 | 0.030 |
Why?
| | Obesity | 1 | 2010 | 2992 | 0.030 |
Why?
| | Protein Binding | 2 | 2022 | 2224 | 0.030 |
Why?
| | Cyclosporine | 1 | 1997 | 268 | 0.030 |
Why?
| | Adenosine | 2 | 1988 | 225 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2021 | 548 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 39 | 0.030 |
Why?
| | Child, Preschool | 3 | 2024 | 11074 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 24 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2014 | 219 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1118 | 0.030 |
Why?
| | Microsomes, Liver | 3 | 1985 | 86 | 0.030 |
Why?
| | Metaplasia | 2 | 2006 | 60 | 0.030 |
Why?
| | Margins of Excision | 1 | 2016 | 50 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 785 | 0.030 |
Why?
| | Pain Management | 1 | 2019 | 352 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1024 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2900 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2008 | 810 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 81 | 0.030 |
Why?
| | Gadolinium DTPA | 2 | 2006 | 70 | 0.030 |
Why?
| | HCT116 Cells | 2 | 2006 | 80 | 0.030 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 52 | 0.030 |
Why?
| | Infection Control | 1 | 2016 | 167 | 0.030 |
Why?
| | Carbon Tetrachloride | 2 | 1985 | 13 | 0.030 |
Why?
| | Vascular Patency | 1 | 2015 | 106 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 136 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2016 | 233 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1020 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2006 | 188 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 992 | 0.030 |
Why?
| | Patient Transfer | 1 | 2016 | 176 | 0.030 |
Why?
| | Phosgene | 2 | 1984 | 7 | 0.030 |
Why?
| | Machine Learning | 1 | 2019 | 493 | 0.030 |
Why?
| | Medical Oncology | 1 | 2016 | 289 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 351 | 0.030 |
Why?
| | Weight Loss | 2 | 2011 | 787 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2013 | 27 | 0.030 |
Why?
| | Chromosomes, Human, X | 1 | 2013 | 73 | 0.030 |
Why?
| | Immunologic Techniques | 1 | 1993 | 40 | 0.030 |
Why?
| | Proteins | 2 | 2012 | 1009 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 945 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2012 | 2 | 0.020 |
Why?
| | Diabetes Mellitus | 2 | 2012 | 1040 | 0.020 |
Why?
| | Heredity | 1 | 2012 | 13 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1993 | 125 | 0.020 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2012 | 18 | 0.020 |
Why?
| | Codon | 1 | 2012 | 89 | 0.020 |
Why?
| | Laser Capture Microdissection | 1 | 2012 | 33 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2011 | 16 | 0.020 |
Why?
| | Gene Dosage | 1 | 2012 | 140 | 0.020 |
Why?
| | Review Literature as Topic | 1 | 2012 | 75 | 0.020 |
Why?
| | Influenza A virus | 1 | 1993 | 107 | 0.020 |
Why?
| | Xanthines | 2 | 1988 | 19 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 66 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 130 | 0.020 |
Why?
| | Periodic Acid-Schiff Reaction | 1 | 2011 | 3 | 0.020 |
Why?
| | Cytodiagnosis | 1 | 2011 | 33 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2011 | 59 | 0.020 |
Why?
| | China | 1 | 2012 | 217 | 0.020 |
Why?
| | Ablation Techniques | 1 | 2011 | 36 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2012 | 170 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2011 | 148 | 0.020 |
Why?
| | Mitosis | 1 | 2012 | 192 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 89 | 0.020 |
Why?
| | Frozen Sections | 1 | 2011 | 26 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 622 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 303 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 657 | 0.020 |
Why?
| | Neprilysin | 1 | 2011 | 47 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 99 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1993 | 363 | 0.020 |
Why?
| | Minnesota | 1 | 2011 | 164 | 0.020 |
Why?
| | Gene Frequency | 1 | 2012 | 521 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 134 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 356 | 0.020 |
Why?
| | Carcinoma, Ductal | 1 | 2010 | 11 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1993 | 353 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 2010 | 32 | 0.020 |
Why?
| | Portugal | 1 | 2010 | 10 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 95 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 141 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2011 | 175 | 0.020 |
Why?
| | Organizational Case Studies | 1 | 2010 | 78 | 0.020 |
Why?
| | Personnel Turnover | 1 | 2010 | 40 | 0.020 |
Why?
| | Fanconi Anemia | 1 | 2010 | 11 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4060 | 0.020 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2010 | 10 | 0.020 |
Why?
| | Genes, p16 | 1 | 2010 | 20 | 0.020 |
Why?
| | Genes, BRCA2 | 1 | 2010 | 31 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2010 | 56 | 0.020 |
Why?
| | Gastric Bypass | 1 | 2011 | 119 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 421 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2011 | 167 | 0.020 |
Why?
| | Attitude to Death | 1 | 2010 | 68 | 0.020 |
Why?
| | Forms and Records Control | 1 | 2009 | 23 | 0.020 |
Why?
| | Professional Practice | 1 | 2009 | 64 | 0.020 |
Why?
| | Diagnosis-Related Groups | 1 | 2009 | 31 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 59 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2010 | 171 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2009 | 17 | 0.020 |
Why?
| | Tamoxifen | 1 | 2010 | 202 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2010 | 297 | 0.020 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 78 | 0.020 |
Why?
| | beta Catenin | 1 | 2011 | 253 | 0.020 |
Why?
| | Genes, p53 | 1 | 2009 | 72 | 0.020 |
Why?
| | Genes, ras | 1 | 2009 | 97 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 172 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2003 | 1250 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 366 | 0.020 |
Why?
| | Family Health | 1 | 2009 | 196 | 0.020 |
Why?
| | Postoperative Care | 1 | 2010 | 261 | 0.020 |
Why?
| | Molecular Probes | 1 | 2008 | 36 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 343 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 620 | 0.020 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2012 | 301 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2181 | 0.020 |
Why?
| | Claudins | 1 | 2008 | 25 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 2010 | 162 | 0.020 |
Why?
| | Anticoagulants | 1 | 2013 | 664 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 82 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 372 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 391 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 329 | 0.020 |
Why?
| | Disease Management | 1 | 2012 | 628 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2011 | 539 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2011 | 307 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 72 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 1060 | 0.020 |
Why?
| | Chronic Disease | 2 | 2003 | 1793 | 0.020 |
Why?
| | Cell Line | 1 | 1993 | 2847 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1916 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 324 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 133 | 0.020 |
Why?
| | Population Surveillance | 1 | 2010 | 482 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2009 | 194 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 2199 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 112 | 0.020 |
Why?
| | Folic Acid Antagonists | 1 | 2006 | 9 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2008 | 230 | 0.020 |
Why?
| | Tetrahydrofolates | 1 | 2006 | 18 | 0.020 |
Why?
| | Gallbladder | 1 | 2006 | 19 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4565 | 0.020 |
Why?
| | Lymphotoxin beta Receptor | 1 | 2006 | 2 | 0.020 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2006 | 4 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 439 | 0.020 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2006 | 6 | 0.020 |
Why?
| | Concanavalin A | 1 | 2006 | 76 | 0.020 |
Why?
| | Evidence-Based Practice | 1 | 2009 | 229 | 0.020 |
Why?
| | Medicare | 1 | 2012 | 773 | 0.020 |
Why?
| | Antigens, Ly | 1 | 2006 | 44 | 0.020 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 18 | 0.020 |
Why?
| | Claudin-4 | 1 | 2006 | 15 | 0.020 |
Why?
| | Halothane | 1 | 1985 | 7 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 556 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2006 | 83 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2006 | 117 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2006 | 154 | 0.020 |
Why?
| | Granzymes | 1 | 2006 | 50 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 164 | 0.020 |
Why?
| | Macrophages | 1 | 2013 | 1547 | 0.020 |
Why?
| | CA-125 Antigen | 1 | 2005 | 14 | 0.020 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 20 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 245 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2010 | 594 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2006 | 164 | 0.010 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2005 | 15 | 0.010 |
Why?
| | Homeostasis | 1 | 2009 | 621 | 0.010 |
Why?
| | Iodized Oil | 1 | 2005 | 4 | 0.010 |
Why?
| | Overweight | 1 | 2010 | 558 | 0.010 |
Why?
| | Exoribonucleases | 1 | 2006 | 49 | 0.010 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 123 | 0.010 |
Why?
| | Epithelium | 1 | 2006 | 313 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 1050 | 0.010 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2004 | 17 | 0.010 |
Why?
| | Methotrexate | 1 | 2006 | 260 | 0.010 |
Why?
| | Family | 1 | 2009 | 671 | 0.010 |
Why?
| | Heme | 1 | 1985 | 78 | 0.010 |
Why?
| | bcl-X Protein | 1 | 2004 | 43 | 0.010 |
Why?
| | Janus Kinase 2 | 1 | 2004 | 32 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 500 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 1431 | 0.010 |
Why?
| | Bile | 1 | 2004 | 34 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 247 | 0.010 |
Why?
| | Biliary Tract Diseases | 1 | 2004 | 39 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1459 | 0.010 |
Why?
| | Histocytological Preparation Techniques | 1 | 2004 | 2 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1226 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 2139 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 1066 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 51 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 1987 | 518 | 0.010 |
Why?
| | Methyl n-Butyl Ketone | 1 | 1983 | 1 | 0.010 |
Why?
| | Chloroform | 1 | 1983 | 4 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2005 | 116 | 0.010 |
Why?
| | Phenobarbital | 1 | 1983 | 19 | 0.010 |
Why?
| | Paraffin Embedding | 1 | 2004 | 32 | 0.010 |
Why?
| | Chile | 1 | 2003 | 24 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1040 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1139 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 233 | 0.010 |
Why?
| | Ketones | 1 | 1983 | 49 | 0.010 |
Why?
| | Rats | 6 | 1988 | 5647 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2003 | 316 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 2389 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2009 | 1171 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 767 | 0.010 |
Why?
| | Rats, Inbred Strains | 3 | 1985 | 362 | 0.010 |
Why?
| | Physicians | 1 | 2009 | 910 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2000 | 40 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2111 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 771 | 0.010 |
Why?
| | Phylogeny | 1 | 2003 | 904 | 0.010 |
Why?
| | Image Enhancement | 1 | 2000 | 190 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5472 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1997 | 50 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6079 | 0.010 |
Why?
| | Antimetabolites | 1 | 1997 | 23 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1997 | 416 | 0.010 |
Why?
| | Drug Interactions | 1 | 1997 | 410 | 0.010 |
Why?
| | Infant | 1 | 2009 | 9465 | 0.010 |
Why?
| | Lymphogranuloma Venereum | 1 | 1951 | 2 | 0.010 |
Why?
| | Neck | 1 | 1951 | 101 | 0.010 |
Why?
| | Phenylisopropyladenosine | 1 | 1987 | 6 | 0.000 |
Why?
| | Chemistry | 1 | 1987 | 45 | 0.000 |
Why?
| | Chemical Phenomena | 1 | 1987 | 83 | 0.000 |
Why?
| | Diglycerides | 1 | 1987 | 61 | 0.000 |
Why?
| | Phosphatidylethanolamines | 1 | 1987 | 77 | 0.000 |
Why?
| | Prodrugs | 1 | 1987 | 52 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1988 | 570 | 0.000 |
Why?
| | Aniline Compounds | 1 | 1987 | 102 | 0.000 |
Why?
| | Electrophoresis | 1 | 1985 | 32 | 0.000 |
Why?
| | Acetylation | 1 | 1985 | 248 | 0.000 |
Why?
| | Fatty Acids | 1 | 1987 | 443 | 0.000 |
Why?
| | Cerebral Cortex | 1 | 1987 | 433 | 0.000 |
Why?
| | Benzphetamine | 1 | 1983 | 1 | 0.000 |
Why?
| | Cell Membrane | 1 | 1987 | 738 | 0.000 |
Why?
| | Chromatography, Ion Exchange | 1 | 1983 | 55 | 0.000 |
Why?
| | Oxidation-Reduction | 1 | 1984 | 1060 | 0.000 |
Why?
| | Oxygen | 1 | 1984 | 931 | 0.000 |
Why?
|
|
Schulick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|